Webinar: how to achieve rapid translation of targets towards the clinic

Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells in vitro, there is now more scope to explore basic immune cell biology coupled with the search for new therapeutics.

A new path to the clinic using CRISPR-Cas screens and cell panel drug screens in target ID and validation, is hosted by DDW and supported by Horizon Discovery. It features the expertise of Palwinder Mander, GSK.

It took place on 6 July 2021. Watch on demand for FREE here.

In this webinar, given by Palwinder Mander from the Immuno-Epigenetics, Adaptive Immunity Research Unit, GSK, Stevenage, UK you will hear how pooled CRISPR-Cas screens combined with target validation using existing drugs can lead to the rapid translation of targets towards the clinic. This webinar will also illustrate how validation of targets in primary immune cells from screens carried our in immune cell lines can help to prioritise the most robust targets.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free